Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer

Cisplatin yields significant efficacy and is generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, acquired resistance strongly limits its application. Here, we identified that a novel histone deacetylase (HDAC) inhibitor S11, with P-glycoprotein inhibitory activity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yuhong, Bao, Xuefei, Ren, Yong, Jia, Lina, Zou, Shenglan, Han, Jian, Zhao, Mengyue, Han, Mei, Li, Hong, Hua, Qixiang, Fang, Yi, Yang, Jingyu, Wu, Chunfu, Chen, Guoliang, Wang, Lihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534535/
https://www.ncbi.nlm.nih.gov/pubmed/31127087
http://dx.doi.org/10.1038/s41419-019-1597-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534535/
https://www.ncbi.nlm.nih.gov/pubmed/31127087
http://dx.doi.org/10.1038/s41419-019-1597-y

Ejemplares similares